Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio; Christophe F. Chantrain; Tanja A. Gruber; Adriana Thano; Fanny Rialland; Audrey Contet; Sarah Elitzur; Luciano Dalla-Pozza; Krisztián Miklós Kállay; Chi kong Li; Motohiro Kato; Inna Markova; Kjeld Schmiegelow; Nicole Bodmer; Erin H. Breese; Raoull  Hoogendijk; Rob Pieters; Christian Michel Zwaan

doi:10.1111/bjh.17333

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio
, Christophe F. Chantrain
, Tanja A. Gruber
, Adriana Thano
, Fanny Rialland
, Audrey Contet
, Sarah Elitzur
, Luciano Dalla-Pozza
, Krisztián Miklós Kállay
, Chi kong Li
, Motohiro Kato
, Inna Markova
, Kjeld Schmiegelow
, Nicole Bodmer
, Erin H. Breese
, Raoull Hoogendijk
, Rob Pieters
, Christian Michel Zwaan^*

^*Corresponding author for this work

Pediatrics

CHC-Clinique du MontLégia - Liège
Stanford University School of Medicine
Princess Máxima Center for Pediatric Oncology
CHU de Nantes
CHU de Nancy
Tel Aviv University
The Children's Hospital at Westmead
Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases
Chinese University of Hong Kong
National Center for Child Health and Development
Pavlov University
Rigshospitalet
University of Zurich
University of Cincinnati

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

Abstract

No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22⁺ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m² (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

Original language	English
Pages (from-to)	1172-1177
Number of pages	6
Journal	British Journal of Haematology
Volume	193
Issue number	6
Early online date	2 Feb 2021
DOIs	https://doi.org/10.1111/bjh.17333
Publication status	Published - Jun 2021

Bibliographical note

Funding Information:
No funding source to disclose. All authors have contributed to the manuscript in significant ways: CMZ and EB designed the study; CFC, TAG, FR, AC, SE, LD-P, KMK, CL, MK, IM, KS, NB and EHB contributed in patient treatment and data collection and interpretation; EB, RH, AT and CMZ contributed to collection and assembly of data and provided data analysis and interpretation; CMZ and EB contributed also to the literature search and editing the manuscript. All authors have both reviewed and agreed on the manuscript content. The authors would like to thank Andrea Biondi and the iBFM network for sharing the study within the collaborative group centres.

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Access to Document

10.1111/bjh.17333Licence: Unspecified

Cite this

Brivio, E., Chantrain, C. F., Gruber, T. A., Thano, A., Rialland, F., Contet, A., Elitzur, S., Dalla-Pozza, L., Kállay, K. M., Li, C. K., Kato, M., Markova, I., Schmiegelow, K., Bodmer, N., Breese, E. H., Hoogendijk, R., Pieters, R., & Zwaan, C. M. (2021). Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. British Journal of Haematology, 193(6), 1172-1177. https://doi.org/10.1111/bjh.17333

@article{20b188c3fded4c76a9017eb43e0ce977,

title = "Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series",

abstract = "No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72\% (range 40–100\%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47\%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47\% (95\% confidence interval [CI] 27–80\%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.",

author = "Erica Brivio and Chantrain, \{Christophe F.\} and Gruber, \{Tanja A.\} and Adriana Thano and Fanny Rialland and Audrey Contet and Sarah Elitzur and Luciano Dalla-Pozza and K{\'a}llay, \{Kriszti{\'a}n Mikl{\'o}s\} and Li, \{Chi kong\} and Motohiro Kato and Inna Markova and Kjeld Schmiegelow and Nicole Bodmer and Breese, \{Erin H.\} and Raoull Hoogendijk and Rob Pieters and Zwaan, \{Christian Michel\}",

note = "Funding Information: No funding source to disclose. All authors have contributed to the manuscript in significant ways: CMZ and EB designed the study; CFC, TAG, FR, AC, SE, LD-P, KMK, CL, MK, IM, KS, NB and EHB contributed in patient treatment and data collection and interpretation; EB, RH, AT and CMZ contributed to collection and assembly of data and provided data analysis and interpretation; CMZ and EB contributed also to the literature search and editing the manuscript. All authors have both reviewed and agreed on the manuscript content. The authors would like to thank Andrea Biondi and the iBFM network for sharing the study within the collaborative group centres. Publisher Copyright: {\textcopyright} 2021 British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2021",

month = jun,

doi = "10.1111/bjh.17333",

language = "English",

volume = "193",

pages = "1172--1177",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

Brivio, E, Chantrain, CF, Gruber, TA, Thano, A, Rialland, F, Contet, A, Elitzur, S, Dalla-Pozza, L, Kállay, KM, Li, CK, Kato, M, Markova, I, Schmiegelow, K, Bodmer, N, Breese, EH, Hoogendijk, R, Pieters, R & Zwaan, CM 2021, 'Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series', British Journal of Haematology, vol. 193, no. 6, pp. 1172-1177. https://doi.org/10.1111/bjh.17333

TY - JOUR

T1 - Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia

T2 - a case series

AU - Brivio, Erica

AU - Chantrain, Christophe F.

AU - Gruber, Tanja A.

AU - Thano, Adriana

AU - Rialland, Fanny

AU - Contet, Audrey

AU - Elitzur, Sarah

AU - Dalla-Pozza, Luciano

AU - Kállay, Krisztián Miklós

AU - Li, Chi kong

AU - Kato, Motohiro

AU - Markova, Inna

AU - Schmiegelow, Kjeld

AU - Bodmer, Nicole

AU - Breese, Erin H.

AU - Hoogendijk, Raoull

AU - Pieters, Rob

AU - Zwaan, Christian Michel

N1 - Funding Information: No funding source to disclose. All authors have contributed to the manuscript in significant ways: CMZ and EB designed the study; CFC, TAG, FR, AC, SE, LD-P, KMK, CL, MK, IM, KS, NB and EHB contributed in patient treatment and data collection and interpretation; EB, RH, AT and CMZ contributed to collection and assembly of data and provided data analysis and interpretation; CMZ and EB contributed also to the literature search and editing the manuscript. All authors have both reviewed and agreed on the manuscript content. The authors would like to thank Andrea Biondi and the iBFM network for sharing the study within the collaborative group centres. Publisher Copyright: © 2021 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2021/6

Y1 - 2021/6

N2 - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

AB - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

UR - https://www.scopus.com/pages/publications/85100188201

U2 - 10.1111/bjh.17333

DO - 10.1111/bjh.17333

M3 - Article

C2 - 33529389

AN - SCOPUS:85100188201

SN - 0007-1048

VL - 193

SP - 1172

EP - 1177

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this